Bioage Labs Inc (BIOA) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Bioage Labs Inc (BIOA) following the 2026 Q2 hedge fund 13F filings?

As of today, BIOA has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BIOA gained -56.8% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Bioage Labs Inc (BIOA)

144 + Investors. Track Smart Money conviction in BIOA. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — BIOA

Based on 145 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q

For 7 consecutive quarters, more hedge funds added BIOA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

145 hedge funds hold BIOA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +123% more funds vs a year ago

fund count last 6Q

+80 new funds entered over the past year (+123% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 68% buying

96 buying45 selling

Last quarter: 96 funds were net buyers (50 opened a brand new position + 46 added to an existing one). Only 45 were sellers (28 trimmed + 17 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+20 vs last Q)

new funds entering per quarter

Funds opening a new BIOA position: 25 → 14 → 30 → 50. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 53% entered in last year

■ 5% conviction (2yr+) ■ 42% medium ■ 53% new

Only 7 funds (5%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Value +89% but shares only +45% — price-driven

Value

+88%

+45%

Last quarter: the total dollar value of institutional holdings rose +89%, but actual share count only changed +45%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

15 → 25 → 14 → 30 → 50 new funds/Q

New funds entering each quarter: 25 → 14 → 30 → 50. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 64% of holders entered in last year

■ 5% veterans ■ 31% 1-2yr ■ 64% new

Of 147 current holders: 94 (64%) entered in the past year, only 7 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

✅

Strong quality — 29% AUM from major funds

29% from top-100 AUM funds

38 of 143 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

5.6

out of 10

Moderate Exit Risk

Exit risk score 5.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	144	112	28.57%
13F Shares	34M	24M	45.37%
Total Value	$590M	$313M	88.71%
New Positions	49	30	+19
Increased Positions	46	39	+7
Closed Positions	17	9	+8
Reduced Positions	27	24	+3
Total Calls	1	2	-50.0%
Total Puts	3	0	100%
PUT/CALL Ratio	3.0	0.0	Bearish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

144

112

28.57%

13F Shares

34M

24M

45.37%

Total Value

$590M

$313M

88.71%

New Positions

+19

Increased Positions

Closed Positions

Reduced Positions

Total Calls

-50.0%

Total Puts

100%

PUT/CALL Ratio

3.0

0.0

Bearish

Institutional Holders (2026 Q2)

144 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BIOA. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 BIOA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Pivotal bioVenture Partners Investment Advisor LLC	5.20%	653,374	$16.0M
2	Octagon Capital Advisors LP	3.85%	1,748,000	$42.8M
3	Cosmic Management, LLC	3.22%	501,833	$12.3M
4	Sands Capital Alternatives, LLC	3.14%	786,353	$19.3M
5	Cormorant Asset Management, LP	3.00%	2,390,605	$58.6M
6	Sofinnova Investments, Inc.	2.91%	2,293,788	$56.2M
7	MPM BioImpact LLC	2.49%	1,667,661	$40.9M
8	Stempoint Capital LP	1.96%	464,171	$11.4M
9	Squadron Capital Management LLC	1.90%	250,000	$6.1M
10	Alessandra Capital Management, LLC	1.62%	93,368	$2.3M
11	Yiheng Capital Management, L.P.	1.43%	170,532	$4.2M
12	Squadron Capital Management LLC	1.18%	155,000	$3.8M
13	NEXTBio Capital Management LP	1.14%	100,732	$2.5M
14	Braidwell LP	0.94%	1,033,129	$25.3M
15	Birchview Capital, LP	0.79%	69,000	$1.7M
16	Sphera Funds Management LTD.	0.68%	213,671	$5.2M
17	Diadema Partners LP	0.62%	200,100	$4.9M
18	a16z Capital Management, L.L.C.	0.56%	3,233,170	$79.2M
19	Ikarian Capital, LLC	0.53%	200,000	$4.9M
20	Diadema Partners LP	0.45%	146,334	$3.6M
21	Verdad Advisers, LP	0.41%	17,394	$426K
22	Ra Capital Management, L.P.	0.36%	1,671,648	$41.0M
23	Orbimed Advisors LLC	0.34%	752,153	$18.4M
24	Integral Health Asset Management, LLC	0.29%	300,000	$7.4M
25	Persistent Asset Partners Ltd	0.27%	37,253	$913K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Bioage Labs Inc (BIOA)

What does the Smart Money Trend signal show for BIOA?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added BIOA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BIOA?

More buyers than sellers — 68% buying: Last quarter: 96 funds were net buyers (50 opened a brand new position + 46 added to an existing one). Only 45 were sellers (28 trimmed + 17 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for BIOA holders?

Strong quality — 29% AUM from major funds: 38 of 143 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BIOA?

Mostly new holders — 53% entered in last year: Only 7 funds (5%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Bioage Labs Inc (BIOA) following the 2026 Q2 hedge fund 13F filings?

As of today, BIOA has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BIOA has gained -56.8% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Bioage Labs Inc (BIOA)

Smart Money Signals — BIOA

Buying streak — 7 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +123% more funds vs a year ago

More buyers than sellers — 68% buying

More new buyers each quarter (+20 vs last Q)

Mostly new holders — 53% entered in last year

Value +89% but shares only +45% — price-driven

Acceleration phase — new buyers rushing in

Early stage — 64% of holders entered in last year

Strong quality — 29% AUM from major funds

Institutional Sentiment Summary — BIOA

Hedge Fund Ownership: BIOA

Market Analysis: BIOA

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: BIOA

Is It Too Late to Buy Bioage Labs Inc (BIOA) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: BIOA

Statistics: BIOA

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Bioage Labs Inc (BIOA)

Welcome to 13Foresight!